Monitor the prospectus supplement for exact offering size and pricing. The dilution overhang is likely to pressure the stock near-term. Given the company's pre-revenue status and reliance on capital markets, this offering signals ongoing cash needs without near-term revenue catalysts.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 3 $4.05entry
- T+1 · 6mo ago 0.00%α −0.41% · $4.05
- T+5 · 5mo ago −7.16%α −3.34% · $3.76
- T+20 · 5mo ago −4.44%α −3.44% · $3.87
- T+60 · 3mo ago −10.62%α −13.12% · $3.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals announced an underwritten public offering of common stock, with an option for underwriters to purchase an additional 15%. The offering size is undisclosed, and proceeds will be used for working capital and general corporate purposes. This dilutive event comes as a clinical-stage biotech with no approved products, raising capital to fund operations.
Key Facts
- NRx Pharmaceuticals intends to offer shares of common stock in an underwritten public offering.
- Underwriter has a 30-day option to purchase up to an additional 15% of shares sold.
- BTIG, LLC is lead bookrunner; Lucid Capital Markets is joint bookrunning manager.
- Proceeds will be used for working capital and general corporate purposes.
- Offering is subject to market conditions; size and terms are not yet disclosed.
- Shares offered under an effective shelf registration statement (Form S-3).
Financial Impact
Undisclosed offering size; dilution will depend on final terms. As a clinical-stage biotech with $167M market cap, even a modest offering (e.g., $20-30M) could dilute existing shareholders by 10-20%.
Risk Factors
- Dilution from the offering could be significant relative to current market cap.
- No disclosed use of proceeds beyond working capital suggests no near-term value-creating catalyst.
- Clinical-stage biotech with no approved products; regulatory and commercial risks remain high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305567 |
Track record
22 reports on NRXP
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers